ArticleBlood2018
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Lymphocyte count and risk of chronic lymphocytic leukemia.Journal of the National Cancer Institute · 2026Article
- European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.British journal of haematology · 2025Article
- Article
- State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.Blood cancer journal · 2025Article
- Immune-related genetic single-nucleotide polymorphisms contribute to prognosis and response to chemotherapy in patients with acute lymphoblastic leukemia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL).Blood cancer journal · 2024Article
- Common and rare variants in genetic susceptibility analysis of mature B-cell neoplasm subtypes by whole exome sequencing.Leukemia · 2024Article
- Clinical Risks for Chronic Lymphocytic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Review
- Article
- Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.American journal of clinical pathology · 2023Article
- The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.Leukemia & lymphoma · 2023Review
- Article
- Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.Blood advances · 2022Article
- Meiotic drive in chronic lymphocytic leukemia compared with other malignant blood disorders.Scientific reports · 2022Article
- Article
- Differential Levels of mRNAs in Normal B Lymphocytes, Monoclonal B Lymphocytosis and Chronic Lymphocytic Leukemia Cells from the Same Family Identify Susceptibility Genes.Oncology and therapy · 2021Article
- The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.Blood · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 10 countries.
Geffen KleinsternDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6148-0421
Nicola J CampHuntsman Cancer Institute and Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Lynn R GoldinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Celine M VachonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Claire M VajdicCentre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.
Silvia de SanjoseCIBER de Epidemiología y Salud Pública, Barcelona, Spain.
J Brice WeinbergDepartment of Medicine and.
Yolanda BenaventeCIBER de Epidemiología y Salud Pública, Barcelona, Spain.
Delphine CasabonneCIBER de Epidemiología y Salud Pública, Barcelona, Spain.
Mark LiebowDivision of General Internal Medicine, Mayo Clinic, Rochester, MN.
Alexandra NietersCenter for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany.
Henrik HjalgrimDepartment of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
Mads MelbyeDepartment of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Hans-Olov AdamiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Paolo BoffettaThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Marc MaynadieRegistre des Hémopathies Malignes de Côte d'Or, INSERM UMR1231, Université de Bourgogne-Franche-Comté, Dijon, France.
James McKayInternational Agency for Research on Cancer, Lyon, France.
Pier Luigi CoccoDepartment of Medical Sciences and Public Health, Occupational Health Section, University of Cagliari, Monserrato, Italy.
Tait D ShanafeltDivision of Hematology and.
Timothy G CallDivision of Hematology and.
Aaron D NormanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Curtis HansonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Dennis RobinsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Kari G ChaffeeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Angela R Brooks-WilsonGenome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
Alain MonnereauRegistre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, INSERM, Team EPICENE, UMR 1219, Bordeaux, France.
Jacqueline ClavelEpidemiology of Childhood and Adolescent Cancers Group, INSERM, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, France.
Martha GlennHuntsman Cancer Institute and Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Karen CurtinHuntsman Cancer Institute and Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Lucia CondeUCL Cancer Institute, London, United Kingdom.
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.
Lindsay M MortonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Wendy CozenDepartment of Preventive Medicine and.
Richard K SeversonDepartment of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
John J SpinelliCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
James B JohnstonDepartment of Medical Oncology, Cancer Care Manitoba, Winnipeg, MB, Canada.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Christine F SkibolaDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Jose F LeisDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ; and.
Neil E KayDepartment of Medical Sciences and Public Health, Occupational Health Section, University of Cagliari, Monserrato, Italy.
Karin E SmedbyDepartment of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Neil CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Susan L SlagerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Mayo Clinic in Florida · USNational Cancer Institute · USInstitut d'Investigació Biomédica de Bellvitge · ESUniversity of Utah · USBC Cancer Agency · CACentre international de recherche sur le cancer · FRDélégation Paris 5 · FRStatens Serum Institut · DKUniversity of Cagliari · ITCancerCare Manitoba · CACRUK Lung Cancer Centre of Excellence · GBDuke Medical Center · USEmory University · USIcahn School of Medicine at Mount Sinai · USInserm · FRKarolinska Institutet · SEKarolinska University Hospital · SEMayo Clinic · USMayo Clinic in Arizona · USUniversity Medical Center Freiburg · DE
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MThe Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MCALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5MMultidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7MMolecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7MMayo Cancer Genetic Epidemiology Training ProgramR25CA092049 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M., VACHON, CELINE M · 2001 to 2018
$5.3MSURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS--SEERN01PC065064 · PC · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G · 1996 to 2000
$4.5MGENETIC EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIAR01CA134674 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J. · 2010 to 2016
$3.8MSURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067008 · PC · UNIVERSITY OF IOWA · PI LYNCH, CHARLES · 1996 to 2000
$3.8MPredicting clinical outcome in individuals with small CLL B cell clonesR01CA197120 · NCI · MAYO CLINIC ROCHESTER · PI KAY, NEIL E, SHANAFELT, TAIT D · 2015 to 2019
$3.0MNCATS NIH HHS UL1 TR000135NCCDPHP CDC HHS U58 DP000807NCI NIH HHS HHSN261201000026CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000140CNCI NIH HHS N01 CO012400NCI NIH HHS N01 PC065064NCI NIH HHS N01 PC067008NCI NIH HHS N01 PC067009NCI NIH HHS N01 PC067010NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA129539NCI NIH HHS R01 CA134674NCI NIH HHS R01 CA154643NCI NIH HHS R01 CA197120NCI NIH HHS R25 CA092049World Health Organization 001
Abstract
Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the InterLymph Consortium. For validation, we used data from 1267 controls from Mayo Clinic and 201 CLL, 95 MBL, and 144 controls with a FH of CLL from the Genetic Epidemiology of CLL Consortium. We used odds ratios (ORs) to estimate disease associations with PRS and c-statistics to assess discriminatory accuracy. In InterLymph, the continuous PRS was strongly associated with CLL risk (OR, 2.49;
Indexed as
Polymorphism, Single NucleotideAdultAgedAged, 80 and overB-LymphocytesFemaleGenetic LociGenetic Predisposition to DiseaseHumansLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedOdds RatioRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.